USFDA, EMA Issue First Joint Guidelines on Safe Use of AI in Drug Development
The move comes as regulators push to expand the use of AI in drug discovery and development to shorten timeline and reduce animal testing.
Written By : sheeba farhat
Published On 2026-01-15 08:32 GMT | Update On 2026-01-15 08:32 GMT
Advertisement
New Delhi: The US Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible use Artificial Intelligence (AI) of in developing medicines, aiming to speed up innovation while safeguarding patients.
The principles, issued on Wednesday, offer broad guidance on how AI should be used to generate and monitor evidence across a drug's lifecycle, from early research and clinical trials to manufacturing and safety surveillance.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.